Translational

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biochemistry #Business #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Precision medicine #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

PrecisionLife identifies 68 genes associated with risk of severe COVID-19

Scientists from AI precision medicine company, PrecisionLife, have found 68 genes associated with risk of developing severe COVID-19 by using its proprietary AI-enabled precision medicine platform to analyse the genomes of 929 patients from the UK Biobank who had a severe response to SARS-CoV-2. Prior to an effective… Read More

#Covid-19 #News

#Academic #Assay development optimisation & technology #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Epidarex announces £100 million UK venture fund to back life science firms

22 June 2020 Epidarex Capital, an international finance firm, has launched a £102 million fund in Edinburgh to invest in emerging life sciences businesses. The fund will build new life science companies using world-class research and innovation from emerging hubs across the UK, including university spinouts. Typical initial investments… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Business #Cell therapy #Cellular assays #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Oncology #Regulatory #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

CatalYm to present data on immunotherapy of cancer at AACR Annual Meeting

19 June 2020 CatalYm will be presenting two abstracts identifying a novel immunoregulatory role for Growth-and-Differentiation Factor 15 (GDF-15) and its effective neutralisation by CTL-002 antibody in cancer at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on 22-24 June. Tumor-derived GDF-15 suppresses T-lymphocyte recruitment… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Business #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Pharmacology #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Dexamethasone identified as potential for treatment of COVID-19 ten weeks ago

AI VIVO, a company combining systems pharmacology and artificial intelligence (AI) to accelerate drug discovery, has announced that its platform identified dexamethasoneas having high potential for the treatment of COVID-19 in April 2020. AI VIVO, a company combining systems pharmacology and artificial intelligence (AI) to accelerate… Read More

#Covid-19 #News

#Academic #Biomarkers #Business #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Molecular medicine #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Mobidiag receives second tranche of financing from European Investment Bank

17 June 2020 This is the second tranche of growth capital loan signed with the European Investment Bank in May 2019. The new funds will be used for the development, manufacture and commercialisation of in vitro diagnostics for infectious diseases Mobidiag, a revenue generating, molecular diagnostics company with… Read More

#News

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

The CRISPR revolution arrives in immuno-oncology

The CRISPR revolution arrives in immuno-oncology By Helen Stewart-Miller and Thomas Hope Volume 21 Issue 2 – Spring 2020 CRISPR-cas9 technology is having an exciting impact on drug discovery as a whole, but more specifically CRISPR presents enormous opportunities in targeted screening for immuno-oncology research. Clustered… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Biomarkers #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Immunology #Oncology #PCR #Precision medicine #Regulatory #RNA #Therapeutics #Translational #Translational chemistry

Antimicrobial resistance threatens to undermine our healthcare system

Antimicrobial resistance threatens to undermine our healthcare system By Dr Peter Jackson Volume 21 Issue 2 – Spring 2020 The immediate global challenge to human health and our economic stability due to coronavirus acts as a stark reminder that infectious disease preparedness cannot be ignored. Read More

#Exclusive Content

#Analysis #Analytical chemistry #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Genetics / genomics #Imaging #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Pathology #Pharmacology #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Target validation #Therapeutics #Translational #Translational chemistry

Innovative glycan imaging methods drive cancer biomarker discovery

Innovative glycan imaging methods drive cancer biomarker discovery By Dr Richard Drake, Dr Anand Mehta and Dr Peggy Angel Volume 21 Issue 2 – Spring 2020 Glycosylation accounts for the majority of post-translational modifications (PTMs) of proteins, and changes in glycosylation are known to play a key role… Read More

#Exclusive Content

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Business #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #High throughput screening #Lead discovery #Medicinal chemistry #Organic chemistry #RNA #Screening #System biology #Systems biology #Toxicology #Translational #Translational chemistry

How sharing compound solubility data can advance drug discovery

By Andrii Lozoniuk Volume 21 Issue 2 – Spring 2020 Gathering compound solubility data is a key step during drug discovery that helps ensure cost-effective screening, yet it is a long process and is often underestimated in terms of difficulty. Global sharing of such data can… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology / Virology & Vaccines #Mass spectrometry / NMR #Metabolomics #Molecular medicine #Oncology #Pharmacogenomics #Pharmacology #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry #Urinary

Harnessing the modified proteome for increased diagnostic power

Harnessing the modified proteome for increased diagnostic power By Dr David Bramwell, Dr Steven Laval and Dr Jane McLeod Relevant biomarkers are vitally important in personalised medicine, guiding patient matching to specific therapies for earlier, easier and more effective disease identification and treatment. Here we trace… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genomics #High Content Screening #High throughput screening #Lead discovery #Oncology #Regulatory #Screening #Sequencing #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Unlocking Clinical Trial Data to Uncover New Therapeutic Opportunities

Unlocking Clinical Trial Data to Uncover New Therapeutic Opportunities By David Wang, Masha Hoffey and Dr Simone Sharma This article discusses opportunities, challenges and best practices in leveraging infrastructure excellence and AI to unlock the value of early or inconclusive clinical trial data. The goal… driving stronger biomarker-based… Read More

#Archive

Bacteriophage
#AI / data analytics / healthtech / informatics #Animal models #Business #Cell therapy #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Microbiome #Oncology #Preclinical #Stem cells #System biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Bitten by the Bug – A flurry of investments fuel microbiome drug discovery

By Dr Alexander C. Maue It has become quite evident that the microbiome has the potential to impact drug discovery in vital ways. In addition to impacting study reproducibility and variability, the microbiome may influence drug efficacy or serve as a therapeutic agent. To… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biomarkers #Business #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Microbiology #Nanomedicine / nanotechnology #Organic chemistry #Pathology #Precision medicine #Preclinical #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

2030 Life Sciences and Health in the Digital Age (Part 1)

2030 Life Sciences and Health in the Digital Age (Part 1) By Dr Steve Arlington and John Wise One of the key ways in which The Pistoia Alliance works with its members is to help them not just deal with the problems of today, but also to… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #High Content Screening #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Orphan drugs #Pharmacology #Precision medicine #Preclinical #QA/QC #Regulatory #RNA #System biology #Systems biology #Toxicology #Translational #Translational chemistry

The Reality of Virtual Pharmaceutical Companies

The Reality of Virtual Pharmaceutical Companies By Dr Stephen Naylor and Dr Kirkwood A. Pritchard Jr We discuss the oxymoronic proposition of a Virtual Pharmaceutical Company (VPC) and the typical adopted business model, as well as provide examples of such companies currently trying to undertake this adventurous… Read More

#Archive

#Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Flow Cytometry #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Translational #Translational chemistry

Flow Cytometry – The advanced systems overcoming drug discovery pain points

Flow Cytometry – The advanced systems overcoming drug discovery pain points By Helen Stewart-Miller and Dr Richard Massey Flow cytometry is an invaluable technique for the characterisation of highly heterogeneous cell populations. Thanks to improvements in throughput, automation and multichannel detection capabilities, recent years have seen… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Molecular medicine #Oncology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

From Genotype to Phenotype: Leveraging functional genomics in oncology

From Genotype to Phenotype: Leveraging functional genomics in oncology By Dr Menelas Pangalos & Steve Rees et al. A challenge in drug discovery is that, at best, only around one in five drug candidates will lead to the launch of a medicine. In 2011, AstraZeneca… Read More

#Archive